Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 7Rectal Neoplasms 5Nasopharyngeal Carcinoma 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms by Site 1

Interventions

pembrolizumab 3toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1camrelizumab 1Taxes 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Locally Advanced or Metastatic Solid Tumors × spartalizumab × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡